KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
September 11 2020 - 7:00AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
announced that it will present at the Cantor Fitzgerald Virtual
Global Healthcare Conference on Thursday, September 17, 2020 at
8:40 am ET.
A live webcast of the presentation will be available on the
Company’s website at www.kalvista.com. An audio archive will be
available on the website for 30 days following the
presentation.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
small molecule protease inhibitors for diseases with significant
unmet need. The initial focus is on inhibitors of plasma
kallikrein, which is an important component of the body’s
inflammatory response and which, in excess, can lead to increased
vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema
(HAE) and diabetic macular edema (DME). The Company has created a
structurally diverse portfolio of oral plasma kallikrein inhibitors
and is advancing multiple drug candidates for HAE as well as DME.
KalVista has selected KVD900 as its program to be advanced as an
on-demand therapy for acute HAE attacks and is conducting a Phase 2
proof-of-concept study in HAE patients with data expected in the
second half of 2020. KVD824 is in development for prophylactic
treatment of HAE and is expected to enter a Phase 2 clinical trial
in the second half of 2020. In DME, an intravitreally administered
plasma kallikrein inhibitor known as KVD001, completed a Phase 2
clinical trial in 2019.
For more information, please visit www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties, including the impact
of COVID-19, that could cause actual results to differ materially
from what we expect. Examples of forward-looking statements
include, among others, potential future clinical trial timing and
results. Further information on potential risk factors that could
affect our business and its financial results are detailed in our
annual report on Form 10-K filed on July 1, 2020 and other reports
as filed from time to time with the Securities and Exchange
Commission. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005060/en/
KalVista Pharmaceuticals, Inc. Leah Monteiro Senior
Director, Corporate Communications & Investor Relations
857-999-0808 leah.monteiro@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024